

## MID AND SOUTH ESSEX MEDICINES OPTIMISATION COMMITTEE (MSEMOC)

### ANDEXANET ALFA FOR REVERSING ANTICOAGULATION FROM APIXABAN OR RIVAROXABAN, NICE TA697, MAY 2021

**RED – RECOMMENDED FOR RESTRICTED USE in Secondary Care**

Name: generic (trade)	What it is	Licensed indications	Decision status	NICE guidance
ANDEXANET ALFA infusion (ONDEXXYA®▼)	Recombinant form of human FXa protein; specific reversal agent for FXa inhibitors	Adult patients treated with a direct factor Xa (FXa) inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding	Final	NICE TA697 – recommended

#### MSEMOC recommendation:

**Andexanet alfa is recommended as an option for reversing anticoagulation from apixaban or rivaroxaban, in accordance with NICE technology appraisal recommendations.**

#### [NICE TA697](#) recommendation:

1.1 Andexanet alfa is recommended as an option for reversing anticoagulation from apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding, only if:

- the bleed is in the gastrointestinal tract, and
- the company provides andexanet alfa according to the commercial arrangement.

1.2 Andexanet alfa is recommended only in research for reversing anticoagulation from apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding in the skull (intracranial haemorrhage; ICH), in the form of an ongoing randomised trial mandated by the regulator.

For further information refer to the [Summary of Product Characteristics for andexanet alfa](#).

Providers commissioned to provide services on behalf of Mid and South Essex CCGs are reminded that they are required to follow the local joint formulary and prescribing guidance, as detailed in the medicines management service specification of their contract.

<b>References</b>	NICE TA697: Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban: <a href="https://www.nice.org.uk/guidance/ta697">https://www.nice.org.uk/guidance/ta697</a>
<b>Acknowledgements</b>	Mid and South Essex CCGs Medicines Management Teams
<b>Version</b>	1.0
<b>Author</b>	HCPMSEMOC working group
<b>Approved by</b>	MSEMOC
<b>Date Approved</b>	July 2021
<b>Review Date</b>	July 2026 or sooner if subject to any new updates nationally